Aurobindo Pharma Limited expects injectables’ revenues to increase to $650-700m over three years from the current $380m with contribution from Europe and emerging markets growing even as injectable margins in the US see a possible decline due to increased competition.
A new plant in Vizag is expected to be commissioned in around a year, with supply directed to Europe and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?